𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis

✍ Scribed by Wilfried H. Nikolaizik; Višnja Jenni-Galović; Martin H. Schöni

Publisher
Springer
Year
1996
Tongue
English
Weight
368 KB
Volume
155
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduced mortality in cystic fibrosis pat
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
✍ Gregory S. Sawicki; James E. Signorovitch; Jie Zhang; Dominick Latremouille-Viau 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

## Abstract ## Background Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been well‐described. This study aimed to assess the association between use of

Falsely elevated serum tobramycin concen
Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin
✍ Okan Elidemir; Stephanie R. Maciejewski; Christopher M. Oermann 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 1 views

A recently developed tobramycin preparation for inhalation (TOBIா, Pathogenesis Corp., Seattle, WA) is widely used in CF patients. It is often used in conjunction with intravenous tobramycin. Renal and ototoxicity associated with the use of tobramycin require that serum drug concentrations be monito

Evaluation of long term tobramycin thera
Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease
✍ U. Paporisz; H. G. Posselt; R. Wönne; W. Ristow; D. Röser; H. Knothe; S. W. Bend 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 493 KB

To nine cystic fibrosis patients with chronic bronchopulmonary infection of severely damaged lungs invaded by Pseudomonas aeruginosa, eleven courses of prolonged tobramycin treatment (5 mg/kg/day) for four to 16 weeks were administered. Pulmonary symptoms improved and a better quality of life was ac

Scintigraphic documentation of an improv
Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease
✍ Carla Colombo; Maria Rita Castellani; William F. Balistreri; Ettore Seregni; Mar 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 851 KB

We have previously documented that ursodeoxycholic acid exerts a beneficial effect on liver function and bile acid metabolism in patients with cystic fi- brosis. We hypothesized that the mechanism of action may be related in part to the choleretic properties of the administered bile acid. We therefo